Skip to main content

Table 3 Tertiles of dietary BCAAs in relation to HbA1c according to the genetic risk score in thirds of nested case-control participants

From: Genetic predisposition to impaired metabolism of the branched chain amino acids, dietary intakes, and risk of type 2 diabetes

GRS

Dietary BCAAs(mg/g protein)

Effect size

P for trend

P for interaction

T1

T2

T3

Total BCAAs

     

0.038

 < 4 (n = 424)

5.90(0.76)

5.82(1.11)

6.09(1.14)

0.10(0.076)

0.18

 

 ≥ 4 (n = 444)

5.68(1.06)

6.01(0.74)*

6.13(1.27)*

0.21(0.071)

0.003

 

Isoleucine

     

0.041

 < 4 (n = 424)

5.89(0.76)

5.82(1.11)

6.10(1.14)

0.10(0.076)

0.13

 

 ≥ 4 (n = 444)

5.68(1.06)

6.02(0.75)*

6.13(1.27)*

0.21(0.072)

0.003

 

Leucine

     

0.050

 < 4 (n = 424)

5.88(0.76)

5.83(1.11)

6.09(1.14)

0.10(0.075)

0.19

 

 ≥ 4 (n = 444)

5.68(1.07)

6.01(0.74)*

6.13(1.27)*

0.21(0.071)

0.003

 

Valine

     

0.114

 < 4 (n = 424)

5.90(0.76)

5.83(1.10)

6.08(1.14)

0.11(0.077)

0.15

 

 ≥ 4 (n = 444)

5.73(0.98)

5.96(0.86)

6.13(1.27)*

0.19(0.072)

0.020

 
  1. General linear model was used for estimation of mean (SD) for HbA1c (%) and linear regression model for β coefficient (SE)
  2. BCAAs, branched chain amino acids; GRS, genetic risk score
  3. Results were adjusted for age, sex, BMI, waist circumference, current drinkers, current smokers, physical activity, diabetes treatment, cardiovascular disease, fruit intakes, poultry intakes, and total energy intakes
  4. ∗Comparing to the lowest dietary intake group, P < 0.05